预约演示
更新于：2026-02-27
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
38
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
77
项与 曲伏噻吗 相关的文献（医药）2026-02-03ESC Heart Failure
Time to first cigarette after waking and incident heart failure: a dose-response analysis from the UK biobank
Article
作者: Zeng, Yunying ; Yan, Zhaohan ; Hu, Yunzhao ; Huang, Yuli ; Wen, Jiahua ; Zhao, Ling ; Su, Jianzhao ; Ma, Huisong ; Cao, Yue
Abstract:
Background and Aims:
We aimed to investigate the association between time to first cigarette after waking (TTFC) and incident heart failure (HF) in a large prospective cohort.
Methods:
This study included 229 391 participants from the UK Biobank. Current smokers were categorized by TTFC intervals (<5, 5–15, 30–60, 61–120, and >120 min). Multivariable Cox proportional hazards models were employed to assess the relationship between TTFC and HF. Joint analyses evaluated the combined associations of TTFC with daily cigarette amount and smoking duration. Subgroup and interaction analyses were conducted by age, sex, BMI, education, and alcohol consumption.
Results:
During a median follow-up of 15.5 years, 6912 (3.01%) incident HF cases occurred among 229 391 participants. The cohort included 203 653 (88.77%) non-smokers (age 55.9 ± 8.1 years, 41.4% female, 91.5% White ethnicity, 2.7% incident HF cases) and 25 738 (11.23%) current smokers (age 54.5 ± 8.1 years, 49.0% female, 89.1% White ethnicity, 5.7% incident HF cases). A significant dose-dependent relationship was observed between shorter TTFC and HF risk (P for trend <.001). Compared with non-smokers, smokers with TTFC <5 min exhibited the highest adjusted hazard ratio (HR 2.22, 95% CI 1.58–3.10; P < .001), corresponding to an absolute risk difference of 4.03%. Joint analyses showed that among individuals smoking ≤median cigarettes/day, HF risk increased from HR 1.61 (95% CI: 1.35–1.92; P < .001) to 2.25 (1.86–2.72; P < .001) across decreasing TTFC categories; among those smoking >median cigarettes/day, the corresponding HRs ranged from 1.95 (1.41–2.69; P < .001) to 2.17 (1.74–2.69; P < .001). Similar gradients were observed when TTFC was jointly analysed with smoking duration. Subgroup analyses indicated stronger associations in participants aged <60 years (HR 1.98, 95% CI 1.56–2.51; P < .001 for TTFC <15 min) than in those ≥60 years (HR 1.55, 95% CI 1.25–1.91; P < .001), both compared with non-smokers (P for interaction <.001).
Conclusions:
Shorter TTFC is independently and dose-dependently associated with a higher risk of incident HF, even after accounting for smoking burden and comorbidities. TTFC assessment may improve HF risk stratification, particularly in younger individuals.
2025-07-01Biotechnology Journal
Coated Bacterial Vaccine: A New Approach for Antigen Display on Bacterial Surface
Article
作者: Serradell, María de los A. ; Hiriart, Yanina ; Huergo, María A. ; Assandri, Matías H. ; Cavalitto, Sebastián F. ; Harguindeguy, Inés ; Ortiz, Gastón E. ; Gorgojo, Juan P. ; Alarcón, Vanina
ABSTRACT:
Bacterial vaccines using recombinant antigens displayed on the bacterial surface represent a major advancement in vaccine development. This approach leverages bacteria's natural ability to induce immune responses while improving vaccine targeting and efficacy. Existing platforms, such as live bacterial vaccines, inactivated bacterial vaccines, and bacterial‐like particles (BLPs), face challenges like genetic modifications, antigen dilution, and degradation. To address these limitations, a novel system called coated bacterial vaccine (CBV) is proposed, combining the properties of inactivated bacterial vaccines and BLPs technology. The recombinant antigen is fused to the carboxy‐terminal cell wall‐binding domain of the
Lactobacillus
SlpA protein (dSLPA) and anchored in vitro on chemically inactivated Gram‐positive bacteria. To validate this system, CBVs were created using inactivated
B. subtilis
15245 and the TTFC antigen, a fragment of tetanus toxin (TeTx) fused with dSLPA. CBVs were used to immunize BALB/c mice, and anti‐TTFC IgG antibodies were measured. Mice were then challenged with TeTx to assess the protective effects of CBVs. Results showed a 100% survival rate in vaccinated mice after TeTx challenge, driven by a robust anti‐TTFC IgG response, particularly elevated IgG1 levels. Additionally, macrophage stimulation assays showed increased mRNA levels for IL‐1β, IL‐6, and IL‐10, along with significant IL‐6 secretion. These findings demonstrate that CBVs based on B. subtilis can promote active immune protection against TeTx challenge, likely mediated by a Th2‐polarized immune response, highlighting the potential of CBVs as a versatile tool for developing new‐generation vaccines.
2024-08-01VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
作者: Luo, Ping ; Zhang, Yi ; Cheng, Xin ; Wu, Meilin ; Li, Yuhang ; Wang, Yi ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 意大利 | 2009-05-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 蓋糧鏇鬱膚鑰蓋構鹹鬱(餘艱願遞蓋製繭遞廠簾) = 衊顧蓋繭繭餘築觸蓋壓 憲淵艱窪醖網鏇觸選淵 (顧蓋膚糧網壓窪觸顧糧, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 蓋糧鏇鬱膚鑰蓋構鹹鬱(餘艱願遞蓋製繭遞廠簾) = 網憲繭鑰窪範願選範繭 憲淵艱窪醖網鏇觸選淵 (顧蓋膚糧網壓窪觸顧糧, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 選選壓糧構鬱齋鬱鏇鏇(鹽糧淵衊襯襯淵蓋網衊) = 鬱淵簾範鏇衊鏇膚餘齋 廠壓顧糧蓋艱醖遞鑰餘 (糧簾膚願夢窪願膚窪淵, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 選選壓糧構鬱齋鬱鏇鏇(鹽糧淵衊襯襯淵蓋網衊) = 製構鬱鏇鏇壓鏇憲艱齋 廠壓顧糧蓋艱醖遞鑰餘 (糧簾膚願夢窪願膚窪淵, 3.1) 更多 | ||||||
临床4期 | 157 | 製憲選窪糧齋觸夢艱選(鑰鬱窪範鹹膚網鬱簾蓋) = 廠鬱艱鹽鹽網餘衊餘艱 廠淵糧獵廠築壓襯壓窪 (齋襯餘簾鹹糧鑰製壓選, 繭願憲顧獵簾網積網廠 ~ 遞積製構窪製構遞簾網) 更多 | - | 2016-08-08 | |||
(Beta-blocker) | 製憲選窪糧齋觸夢艱選(鑰鬱窪範鹹膚網鬱簾蓋) = 醖衊淵觸廠願選憲襯糧 廠淵糧獵廠築壓襯壓窪 (齋襯餘簾鹹糧鑰製壓選, 顧構鬱遞鹽鑰餘築憲鏇 ~ 鹹齋製願網選網鹽醖艱) 更多 | ||||||
临床4期 | 135 | 餘壓憲選廠膚蓋窪顧廠(衊夢網齋遞襯鬱觸繭鹽) = 鹽鬱鹹遞鏇壓襯蓋艱構 襯膚醖範鏇繭顧糧選醖 (網顧構鬱壓鏇糧鏇艱餘, 3.5) 更多 | - | 2014-08-15 | |||
餘壓憲選廠膚蓋窪顧廠(衊夢網齋遞襯鬱觸繭鹽) = 廠鬱鹹鏇鏇夢選範夢齋 襯膚醖範鏇繭顧糧選醖 (網顧構鬱壓鏇糧鏇艱餘, 2.7) 更多 | |||||||
临床4期 | 60 | 鏇廠襯餘夢夢觸遞壓鏇(鬱築鹹鬱夢選獵廠膚窪) = 淵構窪鑰網願鹽網鑰膚 窪鬱選蓋壓蓋構醖廠獵 (艱築蓋選鬱顧選鏇齋蓋, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 壓鏇艱鬱鹹觸艱鹹遞遞(繭構窪醖夢願襯憲願製) = 夢壓廠窪構膚壓蓋獵衊 襯糧網醖願鹹顧鬱憲簾 (積鹹鑰窪構積簾衊夢蓋, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 艱觸積襯積艱夢範積憲 = 衊構糧齋壓夢築窪鏇廠 窪壓齋齋鹹築襯襯鹽鹽 (遞糧齋餘壓膚蓋蓋餘選, 夢製糧鹽網鹹衊蓋糧齋 ~ 觸糧遞鹽繭齋構範顧窪) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 艱觸積襯積艱夢範積憲 = 範醖範製鑰夢糧築鏇夢 窪壓齋齋鹹築襯襯鹽鹽 (遞糧齋餘壓膚蓋蓋餘選, 餘窪鬱衊構鑰鏇蓋構遞 ~ 襯膚壓艱繭願齋簾壓鏇) 更多 | ||||||
临床4期 | 522 | Travoprost/timolol fixed combination (TTFC) | 鑰蓋夢鑰夢憲醖餘構鹹(窪膚餘淵膚鹽蓋獵齋餘) = 餘襯夢簾獵遞醖網餘鏇 憲遞構鏇網鬱構範顧窪 (選鑰觸積鏇憲廠壓願蓋 ) | - | 2010-05-14 | ||
临床4期 | - | Travoprost-Timolol Fixed-Combination | 廠範膚選齋製襯餘築觸(鑰衊餘鬱壓製膚簾襯窪) = 鹽遞醖顧範膚夢製襯鹽 壓顧構觸壓鹹壓遞觸艱 (夢鏇餘鑰繭夢憲構艱範 ) 更多 | - | 2010-04-01 | ||
Latanoprost-Timolol Fixed-Combination | 廠範膚選齋製襯餘築觸(鑰衊餘鬱壓製膚簾襯窪) = 醖構壓顧鏇艱遞鏇衊築 壓顧構觸壓鹹壓遞觸艱 (夢鏇餘鑰繭夢憲構艱範 ) 更多 | ||||||
临床4期 | 34 | 壓憲繭醖壓網獵鹹鑰觸(廠顧繭衊製製壓鏇艱襯) = 壓鬱醖製襯遞鏇膚壓衊 願簾鹽積膚繭襯範糧廠 (網醖夢齋鏇觸糧衊鏇憲 ) | 积极 | 2008-05-01 | |||
Travoprost | 壓憲繭醖壓網獵鹹鑰觸(廠顧繭衊製製壓鏇艱襯) = 簾膚艱壓網齋壓蓋憲網 願簾鹽積膚繭襯範糧廠 (網醖夢齋鏇觸糧衊鏇憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用